Chapter 15: Medicines optimization: ensuring quality and safety
Skip chapter table of contents and go to main content
Transdermal (percutaneous) administration
Definition
Transdermal drug delivery is the application of a formulation to the skin for absorption into the systemic circulation (Aulton and Taylor [16]). Medication is applied to the outermost layer of the skin (the stratum corneum) as a patch, ointment, cream or paste. Most transdermal products are designed for a systemic effect but some are designed for a local effect, such as non‐steroidal anti‐inflammatory drug (NSAID) creams designed to act within a joint.
Related theory
Transdermal ointments, creams and pastes
Transdermal ointments, creams and pastes consist of a semisolid medicine such as a paste or ointment where a quantity, usually specified in terms of length, is measured and rubbed into the skin. It can be rubbed into any non‐hairy area of skin. However, where a local effect is required (e.g. for NSAID gels) then the quantity should be rubbed over the affected area(s). Drugs that can be delivered in this way include glyceryl trinitrate and oestradiol. Disadvantages of transdermal preparations in these forms include that they can be messy for patients and can also result in variations of the dose delivered due to the amount applied, the amount of rubbing in of the product and the amount of product transferred onto clothing.
Transdermal patches
Numerous types of transdermal patch exist and their properties differ, so it is important to use them as directed. A transdermal patch (Figure 15.11) contains a certain amount of drug and delivers it in a controlled manner over a specific period of time that is sufficient to cause the desired pharmacological effect when the drug passes through the skin and systemically into the body. A major advantage of all transdermal patch systems is to deliver a drug at a constant rate over a prolonged period of time (Aulton and Taylor [16]). Drugs that can be delivered via a transdermal system include fentanyl, hyoscine, nicotine, rivastigmine, rotigotine and oestradiol (Aulton and Taylor [16]).
Three types of transdermal patch are available: drug in adhesive patches, drug in matrix patches and rate‐limiting membrane‐type patches.
Drug in adhesive patches
These are simply designed patches that consist of a drug‐containing adhesive and a backing material. They are widely used to deliver nicotine, oestradiol and glyceryl trinitrate. They tend to be thinner and more flexible than other patches and this may aid patient comfort and hence adherence. Various daily doses can be delivered, and the patches can be designed to deliver their drug over different periods of time, such as up to 1 day for nicotine patches and up to 7 days for buprenorphine, granisetron and oestradiol (Aulton and Taylor [16]).
Drug in matrix patches
In these patches, the drug is contained within a separate matrix that can be designed to either increase the drug content or control the drug release (Aulton and Taylor [16]). These patches consist of a drug‐containing matrix, an adhesive layer and a backing material. The drug‐containing matrix controls the release of the drug from the system (Aulton and Taylor [16]).
Rate‐limiting membrane‐type patches
These are more complex patches where the drug is contained within a reservoir and the release of the drug is controlled through a semi‐permeable membrane. The reservoir may be liquid or a gel. A characteristic of this type of patch is that it can be designed to contain a high drug load.
Evidence‐based approaches
The advantages of transdermal systems include the following:
- avoidance of drug loss due to first‐pass metabolism
- the drug's effects can be maintained within the therapeutic window for longer, which reduces side‐effects and maintains constant dosing
- potentially improved patient compliance
- the drug's effects can be stopped with the withdrawal of the patch and avoidance of first‐pass metabolism (Aulton and Taylor [16]).
First‐pass metabolism occurs when a drug is absorbed from the GI tract and enters the hepatic portal system and thus the liver before it reaches the rest of the body. The liver metabolizes many drugs, thus reducing their bioavailability before they reach the rest of the circulatory system (Hardman et al. [118]).
A disadvantage of transdermal systems is the limited number of drugs for which the system is suitable; for example, drugs have to have suitable physical and chemical properties to allow them to be absorbed through the skin and exert their effect. Tolerance‐inducing drugs need a period during which they are not administered, which is not always possible with transdermal systems. In addition, drugs to be used in transdermal systems cannot be irritating to the skin otherwise they will not be tolerated by patients (Hillery et al. [128]).
Pre‐procedural considerations
Specific patient preparation
The condition of the affected site should be assessed for altered skin integrity as applying medicines to broken skin can cause too‐rapid absorption, resulting in systemic effects (Perry [281]). The affected area must be washed and dried before applying the patch or ointment. Both patches and ointments should be applied to a hairless area of skin. The upper chest, upper arms and upper back are recommended sites and the distal areas of the extremities should be avoided (Chernecky et al. [39]). For local use (e.g. NSAID ointment) they should be applied to the relevant area of the body. Patches should not be trimmed or cut. It is important to remove previously applied patches as they will have residual drugs, which will continue to be absorbed and may lead to adverse effects.
Procedure guideline 15.4
Medication: transdermal applications
Post‐procedural considerations
Ongoing care
A different skin site should be used each time to avoid skin irritation (Chernecky et al. [39]). After use, the patch still contains substantial quantities of active ingredients, which may have harmful effects if they reach the aquatic environment. Hence, after removal, the used patch should be folded in half (adhesive side inwards so that the release membrane is not exposed), placed in the original sachet (if still available) and then discarded safely out of reach of children. Any used or unused patches should be discarded according to local policy or returned to the pharmacy. Used patches should not be flushed down the toilet or placed in liquid waste disposal systems.
Complications
See ‘Topical applications’ above.